Skip to content

Cheng-Ta Li

31 papers in the library · 431 citations · publishing 2011-2026

Papers

Sort Most recent Most cited

Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.

Psychiatry Research November 2018 Mu-Hong Chen, Cheng-Ta Li, Wei-Chen Lin et al.

Increasing evidence supports the rapid antidepressant effect of a low-dose ketamine infusion in treatment-resistant depression (TRD). Proinflammatory cytokines play a crucial role in the pathophysiology of TRD. However, it is unknown whether the rapid antidepressant effect of ketamine is related to the rapid suppression of proinflammatory cytokines. Seventy-one patients with TRD were randomized...

Identifying Ketamine Responses in Treatment-Resistant Depression Using a Wearable Forehead EEG

arXiv Preprint Archive May 29, 2018 Zehong Cao, Chin-Teng Lin, Weiping Ding et al. preprint

This study explores the responses to ketamine in patients with treatment-resistant depression (TRD) using a wearable forehead electroencephalography (EEG) device. We recruited fifty-five outpatients with TRD who were randomised into three approximately equal-sized groups (A: 0.5 mg/kg ketamine; B: 0.2 mg/kg ketamine; and C: normal saline) under double-blind conditions. The ketamine responses...

Full text (opens in new tab) Eess.sp Biomedical-sensors Depression-treatment Brain-wave-analysis +1

Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study.

Journal of Affective Disorders January 1, 2018 Mu-Hong Chen, Cheng-Ta Li, Wei-Chen Lin et al.

A single low-dose ketamine infusion exhibited a rapid antidepressant effect within 1h. Despite its short biological half-life (approximately 3h), the antidepressant effect of ketamine has been demonstrated to persist for several days. However, changes in brain function responsible for the persistent antidepressant effect of a single low-dose ketamine infusion remain unclear METHODS: Twenty-four...

Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies.

Frontiers in Psychiatry 2018 Cheng-Ta Li, Kai‐Chun Yang, Wei-Chen Lin

Excessive glutamate release has been linked to stress and many neurodegenerative diseases. Evidence indicates abnormalities of glutamatergic neurotransmission or glutamatergic dysfunction as playing an important role in the development of many major psychiatric disorders (e.g., schizophrenia, bipolar disorder, and major depressive disorder). Recently, ketamine, an N-methyl-d-aspartate...

DOI: 10.3389/fpsyt.2018.00767 (opens in new tab) Full text (opens in new tab) Nmda antagonist Antidepressant Glutamate Major psychiatric disorders +1

Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression.

Neuropsychopharmacology December 2017 Tung-Ping Su, Mu-Hong Chen, Cheng-Ta Li et al.

The antidepressant effects of ketamine are thought to depend on brain-derived neurotrophic factor (BDNF) genotype and dose. The purpose of this study was to characterize the dose-related antidepressant effects of ketamine in patients with treatment-resistant depression drawn from a Chinese population predominately possessing lower activity BDNF genotypes (Val/Met, Met/Met). We conducted a...

Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers

Molecular Psychiatry July 12, 2011 J. Hirvonen, R. Goodwin, Cheng-Ta Li et al.

Chronic cannabis (marijuana, hashish) smoking can result in dependence. Rodent studies show reversible downregulation of brain cannabinoid CB1 (cannabinoid receptor type 1) receptors after chronic exposure to cannabis. However, whether downregulation occurs in humans who chronically smoke cannabis is unknown. Here we show, using positron emission tomography imaging, reversible and regionally...